Yang Jie, Kong Fanming
Department of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300381, China.
National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin 300381, China.
Zhongguo Fei Ai Za Zhi. 2025 May 20;28(5):391-399. doi: 10.3779/j.issn.1009-3419.2025.102.18.
Malignant pleural mesothelioma (MPM) is a highly aggressive malignancy originating from mesothelial cells of the pleura, primarily associated with asbestos exposure, and is often characterized by poor prognosis. Due to the lack of specific clinical manifestations in the early stages, the diagnosis of MPM presents a significant challenge, leading to most patients being diagnosed at an advanced stage, which limits the effectiveness of surgical treatment. Consequently, systemic therapies are commonly required. Although Pemetrexed in combination with Platinum-based chemotherapy remains the first-line standard treatment for unresectable MPM, its therapeutic efficacy is limited, and more effective treatment strategies are urgently needed. In recent years, immune checkpoint inhibitors have made significant progress in the treatment of MPM, markedly improving patient survival outcomes. With the increasing depth of molecular biological research on MPM, targeted therapies offer promising personalized treatment options. Additionally, the therapeutic potential of novel strategies such as cell therapy and oncolytic virus therapy is beginning to emerge. This review summarizes the latest advancements in the medical treatment of MPM and looks forward to future therapeutic directions, aiming to provide insights for clinical practice. .
恶性胸膜间皮瘤（MPM）是一种起源于胸膜间皮细胞的高度侵袭性恶性肿瘤，主要与接触石棉有关，其预后通常较差。由于早期缺乏特异性临床表现，MPM的诊断面临重大挑战，导致大多数患者在晚期才被诊断出来，这限制了手术治疗的效果。因此，通常需要进行全身治疗。尽管培美曲塞联合铂类化疗仍然是不可切除MPM的一线标准治疗方法，但其治疗效果有限，迫切需要更有效的治疗策略。近年来，免疫检查点抑制剂在MPM治疗方面取得了显著进展，显著改善了患者的生存结局。随着对MPM分子生物学研究的不断深入，靶向治疗提供了有前景的个性化治疗选择。此外，细胞治疗和溶瘤病毒治疗等新策略的治疗潜力也开始显现。本文综述了MPM医学治疗的最新进展，并展望了未来的治疗方向，旨在为临床实践提供参考。
